Security record · archived quarter
RIGL
Rigel Pharmaceuticals, Inc. · Healthcare · Biotechnology
3Tracked holders
-2Δ holders
554.02KShares held
$8.97MReported value
+0New positions
−2Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | -2 | 9.47M | $370.29M | +3 | −5 |
| Q1 2026 | 77 | -10 | 11.13M | $301.00M | — | −10 |
| Q4 2025 | 86 | +1 | 11.49M | $491.92M | +1 | — |
| Q3 2025 | 18 | +3 | 6.87M | $194.53M | +3 | — |
| Q2 2025 | 12 | +2 | 4.47M | $83.70M | +2 | — |
| Q1 2025 | 7 | -1 | 1.55M | $27.81M | +2 | −3 |
| Q4 2024 | 8 | +4 | 1.41M | $23.66M | +5 | −1 |
| Q3 2024 | 3 | -2 | 554.02K | $8.97M | — | −2 |
| Q2 2024 | 5 | — | 605.71K | $4.98M | — | — |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 399.66K | +2.3% | $6.47M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 399.66K | +2.3% | $6.47M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 141.95K | -2.1% | $2.30M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 12.41K | +9.8% | $201,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Millennium Management | $349,079 | was 0.0% |
| Citadel Advisors | $133,230 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 15.81M shares, $391.97M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API